Dispatch Bio launched with $216 million in funding and a novel immunotherapy platform aiming to target a broad range of solid tumors. The company’s technology uses a viral vector to deliver a universal antigen called Flare that tags tumor cells, directing engineered immune cells to seek and destroy these cancer cells while sparing healthy tissue. Cofounded by immunotherapy pioneers including CAR-T developer Carl June, Dispatch plans to initiate clinical testing next year. The startup addresses challenges in treating “cold” tumors that evade current immunotherapies and has garnered significant venture investor support.